SELP and neoplasm: A promising approach to overcoming this limitation is introducing fucoidan-based nanoparticles with specified characteristics that can be changed to adjust the parameters of pharmacokinetics, as well as accumulation of fucoidan derivatives in the tumor due to binding with P-selectin [98].